3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
The CDMO upgrade represents a transformational step for Remedium Lifecare
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs’ proprietary Oral Thin Film technology platform, ThinOral
Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
This will lead to the consolidation and optimization of the company's operations related to the manufacturing of ampoules and vials
Subscribe To Our Newsletter & Stay Updated
